MBX Biosciences to Participate in Upcoming November Investor Conferences
MBX Biosciences (NASDAQ: MBX), a clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders, has announced its participation in three major investor conferences in November 2024. The company will attend the Guggenheim Inaugural Healthcare Innovation Conference in Boston (Nov 12), the Stifel 2024 Healthcare Conference in New York (Nov 18), and the Jefferies London Healthcare Conference (Nov 20). Each session will feature either a fireside chat or company presentation format. Live webcasts will be available on the MBX Biosciences investor website, with replays accessible for approximately 90 days after each event.
MBX Biosciences (NASDAQ: MBX), un'azienda biofarmaceutica in fase clinica che sviluppa terapie peptidiche di precisione per disturbi endocrini e metabolici, ha annunciato la sua partecipazione a tre importanti conferenze per investitori nel novembre 2024. L'azienda parteciperà alla Conferenza Inaugurale sull'Innovazione Sanitaria di Guggenheim a Boston (12 novembre), alla Conferenza Sanitaria 2024 di Stifel a New York (18 novembre) e alla Conferenza Sanitaria di Jefferies a Londra (20 novembre). Ogni sessione presenterà un incontro informale o una presentazione aziendale. Le dirette delle conferenze saranno disponibili sul sito web per investitori di MBX Biosciences, con le registrazioni accessibili per circa 90 giorni dopo ogni evento.
MBX Biosciences (NASDAQ: MBX), una empresa biofarmacéutica en etapa clínica que desarrolla terapias peptídicas de precisión para trastornos endocrinos y metabólicos, ha anunciado su participación en tres importantes conferencias para inversores en noviembre de 2024. La empresa asistirá a la Conferencia Inaugural de Innovación en Salud de Guggenheim en Boston (12 de noviembre), a la Conferencia de Salud 2024 de Stifel en Nueva York (18 de noviembre) y a la Conferencia de Salud de Jefferies en Londres (20 de noviembre). Cada sesión contará con un chat informal o una presentación de la empresa. Las transmisiones en vivo estarán disponibles en el sitio web para inversores de MBX Biosciences, con repeticiones accesibles durante aproximadamente 90 días después de cada evento.
MBX 바이오사이언스 (NASDAQ: MBX)는 내분비 및 대사 질환을 위한 정밀 펩타이드 치료제를 개발하는 임상 단계의 생물 의약품 회사로, 2024년 11월에 진행되는 세 가지 주요 투자자 회의에 참여한다고 발표했습니다. 이 회사는 보스턴에서 열리는 구겐하임 첫 혁신 의료 회의 (11월 12일), 뉴욕에서 열리는 스티펠 2024 의료 회의 (11월 18일), 런던에서 열리는 제퍼리스 의료 회의 (11월 20일)에 참석할 예정입니다. 각 세션은 화상 간담회 또는 회사 발표 형식으로 진행됩니다. 라이브 웹캐스트는 MBX 바이오사이언스 투자자 웹사이트에서 제공되며, 각 이벤트 후 약 90일 동안 재생이 가능합니다.
MBX Biosciences (NASDAQ: MBX), une entreprise biopharmaceutique en phase clinique développant des thérapies par peptides de précision pour les troubles endocriniens et métaboliques, a annoncé sa participation à trois importantes conférences pour investisseurs en novembre 2024. L’entreprise assistera à la Conférence Inaugurale sur l’Innovation en Santé de Guggenheim à Boston (12 novembre), à la Conférence de Santé 2024 de Stifel à New York (18 novembre) et à la Conférence de Santé de Jefferies à Londres (20 novembre). Chaque session comportera un échange informel ou une présentation de l'entreprise. Des diffusions en direct seront disponibles sur le site dédié aux investisseurs de MBX Biosciences, avec des rediffusions accessibles pendant environ 90 jours après chaque événement.
MBX Biosciences (NASDAQ: MBX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das präzise Peptidtherapien für endokrine und metabolische Erkrankungen entwickelt, hat seine Teilnahme an drei wichtigen Investorenkonferenzen im November 2024 angekündigt. Das Unternehmen wird an der Guggenheim Inaugural Healthcare Innovation Conference in Boston (12. November), der Stifel 2024 Healthcare Conference in New York (18. November) und der Jefferies London Healthcare Conference (20. November) teilnehmen. Jede Sitzung wird in Form eines informellen Gesprächs oder einer Unternehmenspräsentation stattfinden. Live-Webcasts werden auf der Investoren-Website von MBX Biosciences verfügbar sein, und die Wiederholungen werden etwa 90 Tage nach jeder Veranstaltung erreichbar sein.
- None.
- None.
CARMEL, Ind., Oct. 28, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that its management team will participate in the following upcoming investor conferences:
Guggenheim Inaugural Healthcare Innovation Conference
Date: Tuesday, November 12, 2024
Format: Fireside chat
Time: 3:30 p.m. EST
Location: Boston, MA
Stifel 2024 Healthcare Conference
Date: Monday, November 18, 2024
Format: Fireside chat
Time: 3:00 p.m. EST
Location: New York, NY
Jefferies London Healthcare Conference
Date: Wednesday, November 20, 2024
Format: Company presentation
Time: 3:30 p.m. GMT
Location: London, UK
Live webcasts can be accessed on the investors section of the MBX Biosciences website at https://investors.mbxbio.com/news-events/events. Access to the webcast replay will be available approximately two hours after the completion of the event and will be archived on the Company’s website for approximately 90 days.
About MBX Biosciences
MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes its lead product candidate MBX 2109, in Phase 2 development for the treatment of chronic hypoparathyroidism (HP); MBX 1416, in Phase 1 development for the treatment of post-bariatric hypoglycemia (PBH); and an obesity portfolio that includes MBX 4291, as well as multiple discovery and pre-clinical candidates in development for the treatment of obesity. The Company is based in Carmel, Indiana. To learn more, please visit the Company website at www.mbxbio.com and follow it on LinkedIn.
About MBX’s Proprietary Precision Endocrine Peptide (PEP™) Platform
MBX was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, the Company designed its proprietary Precision Endocrine Peptide™ (PEP™) platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients. PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing.
Media Contact:
Kate Burdick
Inizio Evoke Comms
kate.burdick@inizioevoke.com
860-462-1569
Investor Contact:
Jim DeNike
MBX Biosciences
jdenike@mbxbio.com
FAQ
What investor conferences will MBX Biosciences (NASDAQ: MBX) attend in November 2024?
How can investors access MBX Biosciences' November 2024 conference presentations?
What time is MBX Biosciences presenting at the Jefferies London Healthcare Conference 2024?
